Hagar Announces Published Clinical Data on GWave Technology
2024年6月20日 - 12:00AM
ビジネスワイヤ(英語)
Dr. Irl B. Hirsch Highlights the Accuracy and
Accessibility of the GWave Continuous Glucose Monitoring Device
HAGAR, the developer of GWave, a revolutionary non-invasive
continuous glucose monitoring technology that uses RF waves to
measure glucose levels in the blood, announces today the
publication of clinical data demonstrating the device’s impressive
accuracy in Diabetes Technology and Therapeutics.
Dr. Irl B. Hirsch, Medical Advisor to HAGAR and Professor of
Medicine at the Diabetes Treatment and Teaching Chair in the
Division of Metabolism, Endocrinology, and Nutrition at the
University of Washington, highlighted findings from recently
published HAGAR clinical studies led by Professor Tirosh of Tel
Aviv University and Professor Navon of the Weizmann Institute of
Science.
This study, recently published in Diabetes Technology &
Therapeutics, highlights the impressive precision of GWave
technology. Among 75 participants—including those with type 1 and
type 2 diabetes, pregnant women, and individuals without
diabetes—97% of GWave readings matched traditional blood glucose
tests, with only 3% showing minor deviations. Two separate GWave
devices showed identical results, emphasizing their reliability. In
detecting low blood sugar, the GWave device accurately tracked
levels down to 42 mg/dL, outperforming other CGMs that took 90
minutes to align with GWave and capillary readings.
A noteworthy aspect of the study involved comparing GWave's
performance with a commercial blood glucose monitoring system. The
analysis showed that GWave's measurements were highly accurate,
with a mean absolute relative difference (MARD) of 6.7%, strongly
correlating with capillary glucose levels. GWave's accuracy matched
the FreeStyle Lite system, with an R² > 0.99 and 98.8% of
results in the ideal range.
Unlike previous attempts by others at RF glucose measurement,
GWave effectively eliminates interferences from other dermal
components. It emits less radiation than a smartphone and uses a
rechargeable battery, eliminating the need for replacements. The
planned commercial version will be integrated into a smartwatch for
convenience.
Integrating GWave into CGM systems promises accurate,
noninvasive glucose monitoring, benefiting those needing precise
insulin dosing and real-time glycemic event detection. This
technology also addresses adherence challenges in type 2 and
gestational diabetes, potentially improving outcomes and quality of
life. Noninvasive CGM systems like GWave could enhance diabetes
screening and management, enabling earlier intervention and better
health results. In addition, CGM devices have increased in
popularity over the years for those in the wellness space who may
be looking at preventative measures for long-term health. GWave
offers an effective, non-invasive manner to help those who may be
pre-diabetic or those individuals without diabetes reduce their
risk with greater knowledge of their overall health and assist
doctors with more accurate information.
HAGAR's breakthrough designation by the FDA in 2021 is a
testament to the company's success and ongoing commitment to
bringing cutting-edge technology to the market. This designation is
pivotal as HAGAR continues to advance its clinical research and
prepare for further studies in the United States and Israel in the
latter half of 2024.
"We are excited to share our latest findings with the medical
community," said Dr. Irl B. Hirsch. "The accuracy and reliability
of the GWave device, as demonstrated in our recent study, are
promising indicators of its potential to transform diabetes
management. This technology represents a significant step forward
in providing patients with a more accessible and non-invasive
method to monitor their glucose levels."
For more information on Hagar and the GWave technology, visit
here.
About HAGAR N.I.G
HAGAR N.I.G. (Non-invasive Glucose Monitoring) is the developer
of GWave, the first non-invasive continuous glucose monitoring
technology that uses RF waves to measure glucose levels in the
blood. GWave First Generation is a third of the size of a
smartphone, which sends glucose readings to the user via a
smartphone app that can easily be shared with their healthcare
provider. GWave’s final product will be a sensor integrated into a
smartwatch.
For more information, visit: https://www.Hagartech.com/
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240619786412/en/
Sarah Shkargi sarah@tnsmediacomms.com